Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...

Pulse Biosciences (PLSE) announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3. “I am excited to announce Jon as our next CFO, further building upon our ...

MIAMI, January 21, 2025--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

Pulse Biosciences has appointed the company's co-chairman, Paul A. LaViolette, as its new chief executive. LaViolette replaces Burke T. Barrett, who was named president and CEO of the medical ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief Financial Officer, with effect from February 3.

Pulse Biosciences has hired Jon Skinner as the bioelectric medicine company's new chief financial officer. Pulse on Tuesday said Skinner most recently served as vice president of financial ...

Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI, January 10, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), ...